Business & Economy · 1 views

BioArctic : Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi ( lecanemab )

STOCKHOLM, Sweden, Jan.

Source finanznachrichten.de AI Summary Updated January 26, 2026

Story intelligence Beta

Freshness Stale Updated January 26, 2026

Confidence Limited Single-outlet story

Coverage Single outlet

Views 1 Community interest

Read time 1 min ~27 words

AI Summary

STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation

Read full article on Finanznachrichten

AI summaries can be wrong sometimes—always verify important details using the source article.

SUPPORT HAPPENINGNOW · Independent AI News Intelligence

SUPPORTER MESSAGE

Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.

Support HappeningNow